Paper Details

  1. Home
  2. Paper Details

Pharmacotherapy for atrial arrhythmias: present and future.

Author: MazziniMichael J, MonahanKevin M

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Atrial fibrillation (AF) is a common heart rhythm problem that can increase the risk of stroke. New drugs are being developed to treat AF, including agents that target specific ion channels in the heart and those with entirely novel mechanisms.
Paper Details　
Original Abstract of the Article :
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. It is associated with significant morbidity, including palpitations, exercise intolerance, congestive heart failure, and increased risk of embolic stroke. Mortality is increased twofold in patients with AF. Ma...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.hrthm.2008.01.023

データ提供：米国国立医学図書館（NLM）

Pharmacotherapy for Atrial Arrhythmias

Atrial fibrillation (AF), a common heart rhythm disorder, can lead to significant health complications, including stroke and heart failure. This review discusses recent advances in pharmacotherapy for the treatment of atrial arrhythmias, highlighting the development of new agents with improved efficacy and safety profiles.

New Horizons in Atrial Arrhythmia Treatment: A Focus on Targeted Therapies

The review emphasizes the development of new drugs that target specific ion channels in the heart, reducing the risk of ventricular arrhythmias and improving tolerability. The authors highlight the potential of drugs with novel mechanisms, such as the gap junction modulator rotigaptide, for treating both ventricular and atrial arrhythmias.

Improving Outcomes: Seeking Safer and More Effective Treatments

The desert of atrial arrhythmia treatment is filled with challenges, but researchers are constantly seeking new oases of hope. This review highlights the promising advances in pharmacotherapy for treating AF. The development of new drugs with targeted mechanisms and improved safety profiles offers a beacon of hope for patients seeking relief from this debilitating condition.

Dr. Camel's Conclusion

This review takes us on a journey through the evolving landscape of atrial arrhythmia treatment. The development of new drugs with improved efficacy and safety profiles is a testament to the unwavering commitment of researchers to finding better ways to manage this common heart rhythm disorder. These advances offer a glimmer of hope for patients seeking a more comfortable and fulfilling life despite the challenges of atrial arrhythmias.

Date :
  1. Date Completed 2008-07-03
  2. Date Revised 2016-12-22
Further Info :

Pubmed ID

18456197

DOI: Digital Object Identifier

10.1016/j.hrthm.2008.01.023

Related Literature

Article Analysis
・Side Effects of dronedarone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.